Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
13 11월 2024 - 10:00PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunologic diseases, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, will participate in a fireside chat
at the upcoming Jefferies London Healthcare Conference on
Wednesday, November 20th at 12:00pm GMT in London, UK.
A webcast of the presentation can be accessed at the following
link: https://wsw.com/webcast/jeff315/atxs/1873536. An archived
replay of the presentation will be available in the investors
section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics: Astria Therapeutics is a
biopharmaceutical company, and our mission is to bring
life-changing therapies to patients and families affected by
allergic and immunologic diseases. Our lead program, navenibart
(STAR-0215), is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241113458379/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Astria Therapeutics (NASDAQ:ATXS)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
